
At the end of 2021 Novo Nordisk hopes to have scraped together a 5-9 percent revenue growth with a 4-8 percent higher operational result, both measured in local currency.
In DKK terms, however, Novo expects the growth will be around 4 percentage points lower as regards the top line and operating profit, according to the pharmaceutical giant's annual financial report published Wednesday morning.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app